GlaxoSmithKline (GSK) (Belgium)

Industry / private company


Location: Wavre, Belgium (BE) BE

ISNI: -

ROR: https://ror.org/00n3pea85

Show on Map:

Long-term follow-up of HIV-1-infected adults who received the F4/AS01(B) HIV-1 vaccine candidate in two randomised controlled trials (2018) Harrer T, Dinges W, Roman F Journal article Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial (2016) Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, Garcia F, Harrer T, Lelievre JD, et al. Journal article Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study (2014) Harrer T, Plettenberg A, Arasteh K, Van Lunzen J, Faetkenheuer G, Jaeger H, Janssens M, et al. Journal article